XERS vs. ENTA, MGNX, CTNM, INZY, NLTX, AQST, RANI, XBIT, CRMD, and VTYX
Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Enanta Pharmaceuticals (ENTA), MacroGenics (MGNX), Contineum Therapeutics (CTNM), Inozyme Pharma (INZY), Neoleukin Therapeutics (NLTX), Aquestive Therapeutics (AQST), Rani Therapeutics (RANI), XBiotech (XBIT), CorMedix (CRMD), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical preparations" industry.
Xeris Biopharma (NASDAQ:XERS) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
Enanta Pharmaceuticals received 170 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.65% of users gave Xeris Biopharma an outperform vote while only 56.47% of users gave Enanta Pharmaceuticals an outperform vote.
Xeris Biopharma has a beta of 2.37, indicating that its stock price is 137% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
Xeris Biopharma has higher revenue and earnings than Enanta Pharmaceuticals. Xeris Biopharma is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma has a net margin of -37.58% compared to Enanta Pharmaceuticals' net margin of -180.76%. Enanta Pharmaceuticals' return on equity of -64.85% beat Xeris Biopharma's return on equity.
Xeris Biopharma currently has a consensus price target of $4.63, suggesting a potential upside of 143.42%. Enanta Pharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 43.50%. Given Xeris Biopharma's stronger consensus rating and higher possible upside, research analysts plainly believe Xeris Biopharma is more favorable than Enanta Pharmaceuticals.
In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Xeris Biopharma. MarketBeat recorded 20 mentions for Enanta Pharmaceuticals and 18 mentions for Xeris Biopharma. Enanta Pharmaceuticals' average media sentiment score of 0.03 beat Xeris Biopharma's score of -0.01 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Xeris Biopharma beats Enanta Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Xeris Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xeris Biopharma Competitors List
Related Companies and Tools
